- Home
- CYBN vs FBRX Comparison
CYBN vs FBRX Comparison
Compare CYBN & FBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CYBN
- FBRX
- Stock Information
- Founded
- CYBN 2019
- FBRX N/A
- Country
- CYBN Canada
- FBRX United States
- Employees
- CYBN N/A
- FBRX N/A
- Industry
- CYBN Pharmaceuticals and Biotechnology
- FBRX Biotechnology: Pharmaceutical Preparations
- Sector
- CYBN Health Care
- FBRX Health Care
- Exchange
- CYBN Nasdaq
- FBRX Nasdaq
- Market Cap
- CYBN 176.5M
- FBRX 154.5M
- IPO Year
- CYBN N/A
- FBRX N/A
- Fundamental
- Price
- CYBN $6.08
- FBRX $10.56
- Analyst Decision
- CYBN Strong Buy
- FBRX Strong Buy
- Analyst Count
- CYBN 3
- FBRX 3
- Target Price
- CYBN $85.00
- FBRX $68.00
- AVG Volume (30 Days)
- CYBN 625.2K
- FBRX 70.4K
- Earning Date
- CYBN 11-12-2025
- FBRX 11-13-2025
- Dividend Yield
- CYBN N/A
- FBRX N/A
- EPS Growth
- CYBN N/A
- FBRX N/A
- EPS
- CYBN N/A
- FBRX N/A
- Revenue
- CYBN N/A
- FBRX N/A
- Revenue This Year
- CYBN N/A
- FBRX N/A
- Revenue Next Year
- CYBN N/A
- FBRX N/A
- P/E Ratio
- CYBN N/A
- FBRX N/A
- Revenue Growth
- CYBN N/A
- FBRX N/A
- 52 Week Low
- CYBN $4.81
- FBRX $4.11
- 52 Week High
- CYBN $13.88
- FBRX $28.68
- Technical
- Relative Strength Index (RSI)
- CYBN 38.92
- FBRX 43.42
- Support Level
- CYBN $6.16
- FBRX $10.65
- Resistance Level
- CYBN $6.55
- FBRX $11.57
- Average True Range (ATR)
- CYBN 0.49
- FBRX 0.85
- MACD
- CYBN -0.06
- FBRX -0.09
- Stochastic Oscillator
- CYBN 12.90
- FBRX 18.83
About CYBN Cybin Inc.
Cybin Inc is a biopharmaceutical company involved in creating safe and effective therapeutics for patients to address a multitude of mental health issues. The Company is a clinical-stage neuropsychiatric company focused on advancing therapies, delivery mechanisms, novel compounds, and protocols as potential treatments for various psychiatric and neurological conditions. The Company is developing technologies and delivery systems aimed at improving the pharmacokinetics of its proprietary molecules while retaining the therapeutic benefit. These new molecules and delivery systems are expected to be studied through clinical trials to confirm safety and efficacy.
About FBRX Forte Biosciences Inc.
Forte Biosciences Inc is a biopharmaceutical company that is advancing through preclinical trials its product candidate, FB-102, which is a proprietary therapeutic molecule with potentially broad autoimmune applications in such indications as graft-versus-host disease (GvHD), vitiligo, alopecia areata, and type 1 diabetes (T1D).